Company Filing History:

31 out of 854

Roussel Uclaf

patents

4 out of 6,662

Hoechst Aktiengesellschaft

patents

3 out of 832,680

Other

patents

Years Active: 1976-1998

Loading Chart...

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5710146 - Cephem derivatives and processes for their manufacture (1998-01-20),

2. 5336776 - 3-acetoxymethyl-7-(iminoacetamideo)-cephalosporanic acid (1994-08-09),

3. 5243043 - Cephalosporins (1993-09-07),

4. 5159070 - Process for the preparation of derivative of (1992-10-27),

5. 5103012 - 3-acetoxymethyl-7-(iminoacetamino)-cephalosporanic acid derivatives (1992-04-07),

6. 5089490 - Cephem derivatives (1992-02-18),

7. 5057512 - 3-amino-2-oxo-azetidine-1-sulfonic acids (1991-10-15),

8. 4992431 - Cephalosporins (1991-02-12),

9. 4988816 - Novel 3-acetoxymethyl-7-(iminoacetamido)-cephalosporanic acid derivatives (1991-01-29),

10. 4900728 - Novel 3-amino-2-oxo-azetidine-1-sulfonic acids (1990-02-13),

11. 4843164 - Aminothiazolyl acetic acid derivatives (1989-06-27),

12. 4758556 - Cephem derivatives (1988-07-19),

13. 4487937 - 2-(2-Substitutedamino-4-thiazolyl)-2-(1-methoxy-isopropoxyimino)-acetic (1984-12-11),

14. 4483981 - Cephalosporanic acid derivatives (1984-11-20),

15. 4476124 - 2-Amino-4-thiazolyl-2-oxyimino-acetamido-bicyclooctene-carboxylic acids (1984-10-09),

Title: Rene Heymes: A Pioneer in Pharmaceutical Innovations

Introduction

Rene Heymes, based in Romainville, France, is a prominent inventor with a remarkable portfolio of 38 patents. His contributions to the field of pharmaceutical sciences have paved the way for innovative treatments against bacterial infections, showcasing his expertise and dedication to medical advancements.

Latest Patents

Among his latest breakthroughs, Heymes developed novel Cephem derivatives, which encompass processes for their manufacture. These compounds feature a specific chemical arrangement, wherein the R2 O group is positioned in the syn-form. His research has led to pharmaceutical formulations that show efficacy against bacterial infections, reflecting his commitment to addressing critical health challenges. Additionally, he has worked on thiazole intermediates for Cephalosporins, resulting in the synthesis of 3-acetoxymethyl-7-(iminoacetamideo)-cephalosporanic acid.

Career Highlights

Rene Heymes' career includes influential positions at Roussel Uclaf and Hoechst Aktiengesellschaft, where he applied his extensive knowledge in medicinal chemistry. His innovative spirit and dedication have enabled him to lead significant research projects, contributing to advancements in antibiotic development and pharmaceutical formulation.

Collaborations

Throughout his career, Heymes has collaborated with notable professionals such as Andre Lutz and Walter Durckheimer. These partnerships have enriched his work, fostering a creative exchange of ideas that have furthered their mutual goals in pharmaceutical research.

Conclusion

Rene Heymes stands out as a significant figure in the world of pharmaceutical innovations. His numerous patents and collaborative efforts highlight the impact of his work in combating bacterial infections. As the field of medicine continues to evolve, inventors like Heymes are crucial in shaping breakthroughs that enhance global health.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.